CJC-1295 + Ipamorelin

Research Use Only

These products are for laboratory research only and not intended for medical use. They must be handled by qualified professionals in controlled laboratory environments. This compound has not been evaluated by the FDA and is not approved for human or veterinary use.

 

CJC-1295 + Ipamorelin FAQ

What purity and format is this CJC-1295/Ipamorelin blend supplied in?

The blend is supplied as a lyophilized (freeze-dried) white powder, typically with each peptide component at ≥98% purity as assessed by HPLC. The combined peptide mass per vial, individual component ratios, and lot-specific certificates of analysis (CoA) including mass spectrometry confirmation, are available upon request to support research documentation requirements.

 

What are the recommended storage conditions for this blend?

The lyophilized blend should be stored at −20 °C in a dry environment, protected from light and moisture. Under these conditions, the lyophilized powder is stable for research timelines consistent with manufacturer specifications. Once reconstituted, aliquots should be stored at 4 °C and used within a short research window (typically 48–72 hours); extended storage of reconstituted solution should be at −20 °C with avoidance of repeated freeze-thaw cycles to preserve peptide integrity.

 

How is this blend reconstituted for in vitro or preclinical in vivo research use?

For research applications, the lyophilized CJC-1295/Ipamorelin blend is typically reconstituted using sterile bacteriostatic water or sterile 0.9% sodium chloride solution. Researchers should direct the solvent gently down the inner wall of the vial and allow the powder to dissolve without agitation. Specific reconstitution volumes will depend on the experimental concentration requirements of the research protocol. This product is supplied for laboratory research use only.

 

What in vitro and practical model systems have been used to study this compound combination? e

Published preclinical research on the individual components has utilized rat and pig pituitary cell primary cultures, GH3 pituitary cell lines, hypophysectomized rat models, and aged rodent models of reduced GH pulsatility. In vitro receptor pharmacology studies have used transfected HEK-293 cells expressing recombinant GHRHR or GHS-R1a. The blend format is used in research contexts where simultaneous dual-receptor pathway stimulation is desired within a single experimental model.

 

Is this product intended for human use or clinical investigation?

No. This product is supplied strictly for in vitro laboratory research and preclinical scientific investigation. It is not approved, intended, or suitable for human or veterinary clinical use, self-administration, dietary supplementation, or therapeutic application. All research use must comply with applicable institutional (IACUC, IRB) and regulatory guidelines governing research peptides.

 

What are the primary molecular targets of CJC-1295 and Ipamorelin?

CJC-1295 is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH) that acts as an agonist at the GHRH receptor (GHRHR), a Gs-coupled GPCR expressed on anterior pituitary somatotroph cells. Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the cognate receptor for ghrelin. The combination allows simultaneous research interrogation of both the GHRH-cAMP and ghrelin-Gq signaling axes in GH secretion biology.

 

Research Findings

Scientific research has identified several key areas where CJC-1295 + Ipamorelin shows promising applications.

 

Key Areas of Research:

Hormonal:

•GH secretion

•IGF-1 elevation

•Pulsatile release

•Pituitary signaling

 

Metabolic:

•Fat metabolism

•Lean mass retention

•Glucose regulation

•Energy utilization

 

Regenerative:

•Tissue repair

•Collagen synthesis

•Cell proliferation

•Recovery acceleration

 

Systemic:

•Sleep quality

•Anti-inflammatory

•Bone density

•Immune modulation

 

These research findings represent ongoing studies and should not be interpreted as medical claims or recommendations.

References & Citations

1. Teichman SL, Neale A, Lawrence B. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006.PMID: 16352683
2. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016.PMID: 26771670
3. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026.PMID: 41490200
4. Timms M, Ganio K, Steel R. A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug Test Anal. 2019.PMID: 30938069

These references are provided for research purposes only. Citations do not imply endorsement or approval of this product for any specific application.